Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy
Authors
Keywords
-
Journal
Future Oncology
Volume 10, Issue 1, Pages 107-122
Publisher
Future Medicine Ltd
Online
2013-12-11
DOI
10.2217/fon.13.168
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of CYP2D6 Polymorphisms on Tamoxifen Responses of Women with Breast Cancer: A Microarray-based Study in Thailand
- (2013) Chonlaphat Sukasem et al. Asian Pacific Journal of Cancer Prevention
- Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen
- (2013) Lisette Binkhorst et al. BREAST CANCER RESEARCH AND TREATMENT
- Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004–2010
- (2012) Stacie B. Dusetzina et al. BREAST CANCER RESEARCH AND TREATMENT
- Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy
- (2012) Solai Elango Damodaran et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Abstract 2671: CYP2D6 polymorphisms are not associated with tamoxifen outcome in premenopausal women with ER positive breast cancer of the POSH cohort
- (2012) Pilar H. Saladores et al. CANCER RESEARCH
- CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8
- (2012) M. P. Goetz et al. CLINICAL CANCER RESEARCH
- Targeting MDR in breast and lung cancer: Discriminating its potential importance from the failure of drug resistance reversal studies
- (2012) Laleh Amiri-Kordestani et al. DRUG RESISTANCE UPDATES
- Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability – considerations for drug development
- (2012) Yurong Lai et al. Expert Opinion on Drug Metabolism & Toxicology
- Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial and Re: CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
- (2012) P. D. P. Pharoah et al. JNCI-Journal of the National Cancer Institute
- CYP2D6 Genotype as a Marker for Benefit of Adjuvant Tamoxifen in Postmenopausal Women: Lessons Learned
- (2012) C. M. Kelly et al. JNCI-Journal of the National Cancer Institute
- Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
- (2012) Y. Nakamura et al. JNCI-Journal of the National Cancer Institute
- Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
- (2012) V. Stanton JNCI-Journal of the National Cancer Institute
- CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
- (2012) James M. Rae et al. JNCI-Journal of the National Cancer Institute
- CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
- (2012) Meredith M. Regan et al. JNCI-Journal of the National Cancer Institute
- The Risk of Recurrence in Breast Cancer Patients Treated with Tamoxifen: Polymorphisms of CYP2D6 and ABCB1
- (2011) L. K. Teh et al. AAPS Journal
- Effect of CYP2D6 polymorphisms on breast cancer recurrence
- (2011) Phuong K. Morrow et al. CANCER
- Functional Polymorphisms in UDP-Glucuronosyl Transferases and Recurrence in Tamoxifen-Treated Breast Cancer Survivors
- (2011) T. P. Ahern et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Association between Genetic Polymorphisms of CYP2D6 and Outcomes in Breast Cancer Patients with Tamoxifen Treatment
- (2011) Hyung Seok Park et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- P-Glycoprotein (ABCB1) Transports the Primary Active Tamoxifen Metabolites Endoxifen and 4-Hydroxytamoxifen and Restricts Their Brain Penetration
- (2011) D. Iusuf et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- CYP2D6 Inhibition and Breast Cancer Recurrence in a Population-Based Study in Denmark
- (2011) T. L. Lash et al. JNCI-Journal of the National Cancer Institute
- Bracelets from cluster bombs
- (2011) Justine Davies LANCET
- The effect ofABCB1genetic variants on chemotherapy response in HIV and cancer treatment
- (2011) Kerry Reed et al. PHARMACOGENOMICS
- Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen
- (2010) Timothy L. Lash et al. ACTA ONCOLOGICA
- Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen
- (2010) Nava Siegelmann-Danieli et al. BREAST CANCER RESEARCH AND TREATMENT
- Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy
- (2010) Alastair M. Thompson et al. BREAST CANCER RESEARCH AND TREATMENT
- Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence
- (2010) Laurent Azoulay et al. BREAST CANCER RESEARCH AND TREATMENT
- CYP2D6 Polymorphisms as Predictors of Outcome in Breast Cancer Patients Treated with Tamoxifen: Expanded Polymorphism Coverage Improves Risk Stratification
- (2010) W. Schroth et al. CLINICAL CANCER RESEARCH
- Impact ofCYP2D6*4genotype on progression free survival in tamoxifen breast cancer treatment
- (2010) Julia Carolin Stingl et al. CURRENT MEDICAL RESEARCH AND OPINION
- Endoxifen, the Active Metabolite of Tamoxifen, Is a Substrate of the Efflux Transporter P-Glycoprotein (Multidrug Resistance 1)
- (2010) W. A. Teft et al. DRUG METABOLISM AND DISPOSITION
- Selective serotonin reuptake inhibitors and adjuvant tamoxifen therapy: risk of breast cancer recurrence and mortality
- (2010) Deirdre Cronin-Fenton et al. Future Oncology
- Association Between CYP2D6 Polymorphisms and Breast Cancer Outcomes
- (2010) Timothy L. Lash JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of Concomitant CYP2D6 Inhibitor Use and Tamoxifen Adherence on Breast Cancer Recurrence in Early-Stage Breast Cancer
- (2010) Vincent O. Dezentjé et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer
- (2010) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Coprescription of Tamoxifen and Medications That Inhibit CYP2D6
- (2010) Kostandinos Sideras et al. JOURNAL OF CLINICAL ONCOLOGY
- Significant Effect of Polymorphisms inCYP2D6andABCC2on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients
- (2010) Kazuma Kiyotani et al. JOURNAL OF CLINICAL ONCOLOGY
- Composite Functional Genetic and Comedication CYP2D6 Activity Score in Predicting Tamoxifen Drug Exposure Among Breast Cancer Patients
- (2010) Silvana Borges et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Membrane transporters in drug development
- (2010) NATURE REVIEWS DRUG DISCOVERY
- Discovery of complex pathways from observational data
- (2010) James W. Baurley et al. STATISTICS IN MEDICINE
- Concordance of metabolic enzyme genotypes assayed from paraffin-embedded, formalin-fixed breast tumors and normal lymphatic tissue
- (2010) Thomas Ahern Clinical Epidemiology
- Hardy-Weinberg Equilibrium Testing of Biological Ascertainment for Mendelian Randomization Studies
- (2009) Santiago Rodriguez et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
- Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
- (2009) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Potential Role of UGT Pharmacogenetics in Cancer Treatment and Prevention
- (2009) Philip Lazarus et al. Annals of the New York Academy of Sciences
- The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users
- (2009) Monique J. Bijl et al. BREAST CANCER RESEARCH AND TREATMENT
- Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort
- (2009) N. Lynn Henry et al. BREAST CANCER RESEARCH AND TREATMENT
- Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment
- (2009) T. Ramón y Cajal et al. BREAST CANCER RESEARCH AND TREATMENT
- Genetic polymorphisms of CYP2D6*10 and CYP2C19*2,*3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen
- (2009) Masatsugu Okishiro et al. CANCER
- No Increase in Breast Cancer Recurrence with Concurrent Use of Tamoxifen and Some CYP2D6-Inhibiting Medications
- (2009) T. P. Ahern et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen
- (2009) Werner Schroth JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- No Association Between CYP2D6*10 Genotype and Survival of Node-negative Japanese Breast Cancer Patients Receiving Adjuvant Tamoxifen Treatment
- (2009) T. Toyama et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Immortal Person-Time in Studies of Cancer Outcomes
- (2009) Timothy L. Lash et al. JOURNAL OF CLINICAL ONCOLOGY
- Colorectal Hepatic Metastases: Adjuvant Chemotherapy and Survival
- (2009) David J. Gallagher et al. JOURNAL OF CLINICAL ONCOLOGY
- Genotype-guided tamoxifen therapy: time to pause for reflection?
- (2009) Timothy L Lash et al. LANCET ONCOLOGY
- Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment
- (2008) Y. Xu et al. ANNALS OF ONCOLOGY
- Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram
- (2008) T L Lash et al. BRITISH JOURNAL OF CANCER
- Comment on ‘Impact ofCYP2D6*10on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy’
- (2008) Timothy L. Lash et al. CANCER SCIENCE
- Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy
- (2008) Kazuma Kiyotani et al. CANCER SCIENCE
- Impaired Tamoxifen Metabolism Reduces Survival in Familial Breast Cancer Patients
- (2008) W. G. Newman et al. CLINICAL CANCER RESEARCH
- Genetic Variations and Haplotypes of ABCC2 Encoding MRP2 in a Japanese Population
- (2008) Kimie Sai et al. Drug Metabolism and Pharmacokinetics
- Tamoxifen: Catalyst for the change to targeted therapy
- (2007) V. Craig Jordan EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started